Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation

Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi’s may have a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shammas, Natalie, Yang, Tiffany, Abidi, Alireza, Amneus, Malaika, Hodeib, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294647/
https://www.ncbi.nlm.nih.gov/pubmed/35866178
http://dx.doi.org/10.1016/j.gore.2022.101044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294647/
https://www.ncbi.nlm.nih.gov/pubmed/35866178
http://dx.doi.org/10.1016/j.gore.2022.101044

Ejemplares similares